Literature DB >> 28193826

The NLRP3 Inflammasome Has a Critical Role in Peritoneal Dialysis-Related Peritonitis.

Nicolas Hautem1, Johann Morelle1,2, Amadou Sow1,2, Cyril Corbet1, Olivier Feron1, Eric Goffin2, François Huaux1, Olivier Devuyst3,2,4.   

Abstract

Bacterial peritonitis remains the main cause of technique failure in peritoneal dialysis (PD). During peritonitis, the peritoneal membrane undergoes structural and functional alterations that are mediated by IL-1β The NLRP3 inflammasome is a caspase-1-activating multiprotein complex that links sensing of microbial and stress products to activation of proinflammatory cytokines, including IL-1β The potential roles of the NLRP3 inflammasome and IL-1β in the peritoneal membrane during acute peritonitis have not been investigated. Here, we show that the NLRP3 inflammasome is activated during acute bacterial peritonitis in patients on PD, and this activation associates with the release of IL-1β in the dialysate. In mice, lipopolysaccharide- or Escherichia coli-induced peritonitis led to IL-1β release in the peritoneal membrane. The genetic deletion of Nalp3, which encodes NLRP3, abrogated defects in solute transport during acute peritonitis and restored ultrafiltration. In human umbilical vein endothelial cells, IL-1β treatment directly enhanced endothelial cell proliferation and increased microvascular permeability. These in vitro effects require endothelial IL-1 receptors, shown by immunofluorescence to be expressed in peritoneal capillaries in mice. Furthermore, administration of the IL-1β receptor antagonist, anakinra, efficiently decreased nitric oxide production and vascular proliferation and restored peritoneal function in mouse models of peritonitis, even in mice treated with standard-of-care antibiotherapy. These data demonstrate that NLRP3 activation and IL-1β release have a critical role in solute transport defects and tissue remodeling during PD-related peritonitis. Blockade of the NLRP3/IL-1β axis offers a novel method for rescuing morphologic alterations and transport defects during acute peritonitis.
Copyright © 2017 by the American Society of Nephrology.

Entities:  

Keywords:  Interleukin-1; anakinra; cytokines; peritoneal membrane; ultrafiltration; vascular permeability

Mesh:

Substances:

Year:  2017        PMID: 28193826      PMCID: PMC5491280          DOI: 10.1681/ASN.2016070729

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  41 in total

1.  Consensus guidelines for the treatment of peritonitis in pediatric patients receiving peritoneal dialysis.

Authors:  B A Warady; F Schaefer; M Holloway; S Alexander; M Kandert; B Piraino; I Salusky; A Tranaeus; J Divino; M Honda; S Mujais; E Verrina
Journal:  Perit Dial Int       Date:  2000 Nov-Dec       Impact factor: 1.756

Review 2.  Inflammasomes in health and disease.

Authors:  Till Strowig; Jorge Henao-Mejia; Eran Elinav; Richard Flavell
Journal:  Nature       Date:  2012-01-18       Impact factor: 49.962

Review 3.  Beyond tissue injury-damage-associated molecular patterns, toll-like receptors, and inflammasomes also drive regeneration and fibrosis.

Authors:  Hans-Joachim Anders; Liliana Schaefer
Journal:  J Am Soc Nephrol       Date:  2014-04-24       Impact factor: 10.121

4.  Recent peritonitis associates with mortality among patients treated with peritoneal dialysis.

Authors:  Neil Boudville; Anna Kemp; Philip Clayton; Wai Lim; Sunil V Badve; Carmel M Hawley; Stephen P McDonald; Kathryn J Wiggins; Kym M Bannister; Fiona G Brown; David W Johnson
Journal:  J Am Soc Nephrol       Date:  2012-05-24       Impact factor: 10.121

Review 5.  Inflammasome adaptors and sensors: intracellular regulators of infection and inflammation.

Authors:  Sanjeev Mariathasan; Denise M Monack
Journal:  Nat Rev Immunol       Date:  2007-01       Impact factor: 53.106

6.  Functional and molecular characterization of a peritoneal dialysis model in the C57BL/6J mouse.

Authors:  Jie Ni; Yvette Cnops; Huguette Debaix; Isabelle Boisdé; Jean-Marc Verbavatz; Olivier Devuyst
Journal:  Kidney Int       Date:  2005-05       Impact factor: 10.612

Review 7.  From bench to bedside and back again: translational research in autoinflammation.

Authors:  Dirk Holzinger; Christoph Kessel; Alessia Omenetti; Marco Gattorno
Journal:  Nat Rev Rheumatol       Date:  2015-06-16       Impact factor: 20.543

Review 8.  Interleukin-1 in the pathogenesis and treatment of inflammatory diseases.

Authors:  Charles A Dinarello
Journal:  Blood       Date:  2011-02-08       Impact factor: 22.113

9.  Pharmacokinetics of anakinra in subjects with different levels of renal function.

Authors:  Bing-Bing Yang; Sharon Baughman; John T Sullivan
Journal:  Clin Pharmacol Ther       Date:  2003-07       Impact factor: 6.875

10.  The role of IL-1β in the early tumor cell-induced angiogenic response.

Authors:  Yaron Carmi; Shahar Dotan; Peleg Rider; Irena Kaplanov; Malka R White; Rona Baron; Shai Abutbul; Monica Huszar; Charles A Dinarello; Ron N Apte; Elena Voronov
Journal:  J Immunol       Date:  2013-03-08       Impact factor: 5.422

View more
  9 in total

Review 1.  Strategies for preventing peritoneal fibrosis in peritoneal dialysis patients: new insights based on peritoneal inflammation and angiogenesis.

Authors:  Zhen Zhang; Na Jiang; Zhaohui Ni
Journal:  Front Med       Date:  2017-08-08       Impact factor: 4.592

2.  Crucial Role of NLRP3 Inflammasome in the Development of Peritoneal Dialysis-related Peritoneal Fibrosis.

Authors:  Erika Hishida; Homare Ito; Takanori Komada; Tadayoshi Karasawa; Hiroaki Kimura; Sachiko Watanabe; Ryo Kamata; Emi Aizawa; Tadashi Kasahara; Yoshiyuki Morishita; Tetsu Akimoto; Daisuke Nagata; Masafumi Takahashi
Journal:  Sci Rep       Date:  2019-07-17       Impact factor: 4.379

3.  Apoptosis inhibitor of macrophage (AIM) contributes to IL-10-induced anti-inflammatory response through inhibition of inflammasome activation.

Authors:  Tae-Hyun Kim; Kyungwon Yang; Minsuk Kim; Hee-Sun Kim; Jihee Lee Kang
Journal:  Cell Death Dis       Date:  2021-01-04       Impact factor: 8.469

4.  Enhanced mPGES-1 Contributes to PD-Related Peritoneal Fibrosis via Activation of the NLRP3 Inflammasome.

Authors:  Qimei Luo; Qinghua Hu; Qingkun Zheng; Lewei Gong; Lijuan Su; Baojun Ren; Yongle Ju; Zhanjun Jia; Xianrui Dou
Journal:  Front Med (Lausanne)       Date:  2021-05-18

Review 5.  GATA6+ Peritoneal Resident Macrophage: The Immune Custodian in the Peritoneal Cavity.

Authors:  Preethi Jayakumar; Andrea Laganson; Meihong Deng
Journal:  Front Pharmacol       Date:  2022-03-23       Impact factor: 5.810

6.  A Clinical Risk Prediction Tool for Peritonitis-Associated Treatment Failure in Peritoneal Dialysis Patients.

Authors:  Surapon Nochaiwong; Chidchanok Ruengorn; Kiatkriangkrai Koyratkoson; Kednapa Thavorn; Ratanaporn Awiphan; Chayutthaphong Chaisai; Sirayut Phatthanasobhon; Kajohnsak Noppakun; Yuttitham Suteeka; Setthapon Panyathong; Phongsak Dandecha; Wilaiwan Chongruksut; Sirisak Nanta
Journal:  Sci Rep       Date:  2018-10-04       Impact factor: 4.379

7.  Mitochondrial Dysfunction Plays a Relevant Role in Pathophysiology of Peritoneal Membrane Damage Induced by Peritoneal Dialysis.

Authors:  Olalla Ramil-Gómez; Ana Rodríguez-Carmona; Jennifer Adriana Fernández-Rodríguez; Miguel Pérez-Fontán; Tamara Ferreiro-Hermida; Mirian López-Pardo; Teresa Pérez-López; María J López-Armada
Journal:  Antioxidants (Basel)       Date:  2021-03-13

8.  Peritoneal dialysis-related peritonitis caused by gram-negative organisms: ten-years experience in a single center.

Authors:  Ying Zeng; Linsen Jiang; Ying Lu; Zhi Wang; Kai Song; Huaying Shen; Sheng Feng
Journal:  Ren Fail       Date:  2021-12       Impact factor: 2.606

9.  Tissue-resident macrophages actively suppress IL-1beta release via a reactive prostanoid/IL-10 pathway.

Authors:  Natacha Ipseiz; Robert J Pickering; Marcela Rosas; Victoria J Tyrrell; Luke C Davies; Selinda J Orr; Magdalena A Czubala; Dina Fathalla; Avril Ab Robertson; Clare E Bryant; Valerie O'Donnell; Philip R Taylor
Journal:  EMBO J       Date:  2020-06-02       Impact factor: 14.012

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.